ANZUPGO

This brand name is authorized in Cyprus, Estonia, France, Italy, Lithuania

Active ingredients

The drug ANZUPGO contains one active pharmaceutical ingredient (API):

1 Delgocitinib UNII 9L0Q8KK220 - DELGOCITINIB

Delgocitinib is a pan Janus kinase (JAK) inhibitor that targets the activity of all four members of the JAK family of enzymes consisting of JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2) in a concentration dependent manner. Read about Delgocitinib

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
ANZUPGO Cream	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
D11AH11		D Dermatologicals → D11 Other dermatological preparations → D11A Other dermatological preparations → D11AH Agents for dermatitis, excluding corticosteroids
Discover more medicines within D11AH11

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 3090248, 3090259
Country: FR	Base de données publique des médicaments	Identifier(s): 61015604
Country: IT	Agenzia del Farmaco	Identifier(s): 051622013, 051622025
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1101302, 1101303